By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


August 5, 2013


Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop


Please click here for job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO


Company News
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials 6/27/2017 6:42:12 AM
Juno (JUNO) Presents TRANSCEND NHL 001 Trial Data At International Conference On Malignant Lymphoma 6/19/2017 4:55:13 AM
Juno (JUNO) Release: Court Decides It Lacks Jurisdiction Before FDA Approval Occurs 6/14/2017 9:15:33 AM
Down but Not Out, Juno (JUNO) Fights Back with Positive CAR-T Results in its JCAR017 Program 6/5/2017 7:54:34 AM
Juno (JUNO) Appoints Jay Flatley To Board Of Directors 5/23/2017 9:06:15 AM
Juno (JUNO) To Present Key Clinical Data Updates On JCAR017 And JCAR014 At The 2017 ASCO Annual Meeting 5/18/2017 8:37:51 AM
Juno (JUNO) Reports First Quarter 2017 Financial Results 5/5/2017 6:34:00 AM
Juno (JUNO) To Report First Quarter 2017 Financial Results On Thursday, May 4 4/28/2017 6:47:25 AM
Juno (JUNO) Appoints Rupert Vessey To Board Of Directors 4/19/2017 8:29:41 AM
Juno (JUNO) Taps Ex-Genentech (RHHBY) Scientist to Head Up R&D at New Bay Area Office 4/17/2017 5:34:41 AM